4.6 Article

The p38 mitogen-activated protein kinase cascade modulates T helper type 17 differentiation and functionality in multiple sclerosis

期刊

IMMUNOLOGY
卷 146, 期 2, 页码 251-263

出版社

WILEY
DOI: 10.1111/imm.12497

关键词

autoimmunity; experimental autoimmune encephalomyelitis/multiple sclerosis; neuroimmunology; signal transduction; T cells

资金

  1. research fellowship FISM - Fondazione Italiana Sclerosi Multipla [cod.2010/B/3, cod.2011/B/3]
  2. Italian Multiple Sclerosis Society FISM - Fondazione Italiana Sclerosi Multipla [cod 2013/R/2, cod.2013/R/23]
  3. Italian Ministry of Health (Progetto Finalizzato)
  4. Italian Association for Cancer Research (AIRC)
  5. Biotechnology and Biological Sciences Research Council [BB/E019188/1] Funding Source: researchfish
  6. BBSRC [BB/E019188/1] Funding Source: UKRI

向作者/读者索取更多资源

The p38 mitogen-activated protein kinase cascade is required for the induction of a T helper type 17 (Th17) -mediated autoimmune response, which underlies the development and progression of several autoimmune diseases, such as experimental autoimmune encephalomyelitis, the animal model of multiple sclerosis (MS). However, the contribution of p38 phosphorylation to human Th cell differentiation has not been clarified. Here we demonstrate that the p38 signalling pathway is implicated in the generation of Th17 lymphocytes from human CD4(+) CD27(+) CD45RA(+) naive T cells, both in healthy donors and in patients affected by the relapsing-remitting form of MS. Our data also indicate that p38 activation is essential for interleukin-17 release from central memory lymphocytes and committed Th17 cell clones. Furthermore, CD4(+) T cells isolated from individuals with relapsing-remitting MS display an altered responsiveness of the p38 cascade, resulting in increased p38 phosphorylation upon stimulation. These findings suggest that the p38 signalling pathway, by modulating the Th17 differentiation and response, is involved in the pathogenesis of MS, and open new perspectives for the use of p38 inhibitors in the treatment of Th17-mediated autoimmune diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据